COVID-19-Associated Liver Injury

Daniel T Gildea; Stephanie M Woo; Corinne E O'Connor; Amol S Rangnekar

doi:10.2147/HMER.S384108

COVID-19-Associated Liver Injury

Hepat Med. 2023 Feb 21:15:1-9. doi: 10.2147/HMER.S384108. eCollection 2023.

Authors

Daniel T Gildea¹, Stephanie M Woo², Corinne E O'Connor³, Amol S Rangnekar⁴

Affiliations

¹ Department of Internal Medicine, MedStar Georgetown University Hospital, Washington, DC, USA.
² Department of Gastroenterology, MedStar Georgetown University Hospital, Washington, DC, USA.
³ Georgetown University School of Medicine, Washington, DC, USA.
⁴ MedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital, Washington, DC, USA.

Abstract

This review analyzes data regarding liver injury associated with COVID-19 infection. We discuss reported effects on the liver from both COVID-19 and COVID-19 treatment as well as pathophysiology, review the potential role of drug-induced liver injury as an etiology of COVID-19-associated liver injury, and touch on other reports of significant outcomes including COVID-19 cholangiopathy and autoimmune hepatitis. Finally, we review the implications of COVID-19 infection in liver transplant recipients.

Keywords: COVID-19; DILI; cholangiopathy; hepatitis; liver; transplant.

Publication types

Review

Grants and funding

No financial support was provided for this article.